Novartis unveils positive study data on Zolgensma gene therapy
Novartis has presented new study data on Zolgensma, its gene therapy treating spinal muscular atrophy (SMA). The data once again underscored the efficacy of this single-dose gene therapy in patients with SMA, according to a press release issued on Monday.
This content was published on
2 minutes
Keystone-SDA
العربية
ar
نوفارتيس السّويسريّة تكشف عن نتائج إيجابيّة لدراسة حول علاج زولجنسما الجّينيّ
The results of the SMART study added to what is known about the use of Zolgensma in patients who are older (1.5 – 9.1 years) and suffer more severely than the children treated in previous clinical trials.
In almost all cases, the motoric milestones of treated patients were maintained or even improved after 52 weeks. Many of these patients had switched therapies, having previously been treated with a different disease-modifying agent.
More
More
Swiss trade deal: Is India changing its tune on pharma patents?
This content was published on
Patent protection for the Swiss pharmaceutical industry has been a key sticking point in a free trade deal with India. What’s changed?
The SMART study is reportedly the first open-label clinical trial of Zolgensma to include previously treated patients. Novartis announced that it will present the data at the Muscular Dystrophy Association (MDA) conference, which is taking place in the US until March 6.
Adapted from German by DeepL/dkk/amav
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Federer-backed On boosts forecast after sneaker demand rises
This content was published on
Swiss footwear company On Holding AG posted strong first-quarter revenue, boosted by demand for its running shoes and new line of training apparel.
Michael Schumacher’s watches fetch CHF4 million at Swiss auction
This content was published on
Watches belonging to Formula 1 great Michael Schumacher sold for around CHF4 million ($4.41 million) at auction house Christie's in Geneva on Tuesday.
Macron will attend Swiss summit on Ukraine, says Zelensky
This content was published on
French President Emmanuel Macron will attend the peace conference on Ukraine at the Swiss Bürgenstock resort next month, according to Volodymyr Zelensky.
Top politician tells ‘corrupt’ Eurovision to stay away from Bern
This content was published on
A social media post by the president of Bern’s cantonal government critical of the Eurovision Song Contest has created waves and will be discussed in the cantonal parliament.
Swiss centre records over 200 victims of human trafficking
This content was published on
Last year 317 people took part in a protection programme run by the Specialist Unit for Trafficking in Women and Women’s Migration (FIZ) in German-speaking Switzerland.
This content was published on
The Geneva-based International Committee of the Red Cross (ICRC) and partners are opening a field hospital in southern Gaza on Tuesday.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Swiss trade deal: Is India changing its tune on pharma patents?
This content was published on
Patent protection for the Swiss pharmaceutical industry has been a key sticking point in a free trade deal with India. What’s changed?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.